Caplin Point Laboratories Limited (CAPLIPOINT.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹2,352.40 (+3.45%) as of
Key statistics
- Market cap
- 178.81B
- P/E (TTM)
- 26.95
- Forward P/E
- 21.25
- EPS (TTM)
- 87.28
- Dividend yield
- 0.35%
- 52-week range
- 1,500.30 – 2,990.00
- Beta
- 0.42
- Revenue (TTM)
- 22.87B
- Profit margin
- 29.09%
- Analyst target
- ₹2,765.00
- Volume
- 87.85k
About Caplin Point Laboratories Limited
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, ophthalmic droppers, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Chennai, India
- Employees
- 4,199
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.